Showing 1221-1230 of 3024 results for "".
- Wearable Bladder Monitoring Device May Help Predict UTIs in Women With MShttps://practicalneurology.com/news/wearable-bladder-monitoring-device-may-help-predict-utis-in-women-with-ms/2474951/At the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers (CMSC), researchers presented promising data on the use of wearable ultrasound (US) technology to monitor urinary retention in women with multiple sclerosis (MS). The study evaluated the use of the DFree device (Dfree; Sa
- Parafoveal OCT Scans Show Promise as Biomarker of MS Progressionhttps://practicalneurology.com/news/parafoveal-oct-scans-show-promise-in-assessing-ms-progression/2473798/Anatomical variations of parafoveal retinal layer thickness measured using optical coherence tomography (OCT) were associated with clinical outcomes in individuals with multiple sclerosis (MS) according to study results presented at the Americas Committee for Treatment and Research in Multiple Sc
- Enhanced EDSS Instrument Helpful in Assessing Disability Progression in People with MShttps://practicalneurology.com/news/researchers-develop-modified-edss-tool-for-improved-measurement-of-pira-in-ms/2473795/In a recent study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, a novel assessment tool for measuring multiple sclerosis (MS) disease progression showed utility for redefining and quantifying progression independent of relapse acti
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific
- OTC Antihistamine Clemastine May Accelerate Disability in Those with Progressive MShttps://practicalneurology.com/news/otc-antihistamine-clemastine-may-accelerate-disability-in-those-with-progressive-ms/2470414/Cutting-edge research has unveiled concerning findings regarding the use of clemastine fumarate in those with progressive multiple sclerosis (MS). The study, conducted by a team of researchers from the National Institutes of Health (NIH) and other institutions, revealed that clemastine fumar
- Ofatumumab Achieves Better Outcomes than Teriflunomide for Relapsing MShttps://practicalneurology.com/news/ofatumumab-achieves-better-outcomes-than-teriflunomide-for-relapsing-ms/2470081/In 2 clinical trials, participants with newly diagnosed relapsing multiple sclerosis (MS) who received ofatumumab (Kesimpta; Novartis; Cambridge, MA) experienced better outcomes in terms of relapse rate, disability progression, and the number of lesions visualized on MRI scans compared with those
- Social Networks May Be a Modifiable Risk Factor for MS Progressionhttps://practicalneurology.com/news/social-networks-may-be-a-modifiable-risk-factor-for-ms-progression/2468812/Using social network surveys to identify patients with stronger vs weaker social networks (SNs), researchers found that persons with multiple sclerosis (MS) who had significantly worse memory, lower IQ, higher disability scores and larger declines in exercise and social activity participation (
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- Hispanic/Latino Patients Experience MS Onset Earlier than White Participants, New Research Suggestshttps://practicalneurology.com/news/hispaniclatino-patients-experience-ms-onset-earlier-than-white-participants-new-research-suggests/2470201/According to research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the age at onset (AAO) of multiple sclerosis (MS) was on average 5 years earlier for Hispanic/Latino patient